Fairvalue-Calculator Fairvalue-Calculator
EN DE

Guangdong Jiaying Pharmaceutical Co (002198) Fair Value & Analysis

Healthcare · CN · Market cap 1.8B CNY

Price¥3.22
Fair Value¥1.18
Upside-63.4%
Quality95/100
Evidence: High Range ¥1.05 – ¥1.53

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Guangdong Jiaying Pharmaceutical Co (002198) currently trades at ¥3.22, while our model-based Fair Value estimate is ¥1.18 — implying the stock looks roughly 63.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Guangdong Jiaying Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines in Mainland China. The company offers medicines primarily for the treatment of throat, cold, orthopedics, rheumatism, gynecology, heat-clearing, tonic, and gastrointestinal diseases. It also provides Shuangliao Houfeng powder, Chongganling tablets, Jiegu Qili tablets (capsules), Shufeng Huoluo tablets, Tiaomeng Huoxue tablets, etc. Guangdong Jiaying Pharmaceutical Co., Ltd. was founded in 2003 and is based in Meizhou, China.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Guangdong Jiaying Pharmaceutical Co (002198) undervalued?
As of Jun 25, 2026, our model estimates a fair value of ¥1.18 versus a price of ¥3.22 — about −63% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 002198?
Our 21-model fair value for Guangdong Jiaying Pharmaceutical Co is ¥1.18 (as of Jun 25, 2026), built from audited fundamentals. The current price is ¥3.22.
What is the quality score of 002198?
Guangdong Jiaying Pharmaceutical Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.